CAMBRIDGE, MA, Kano Therapeutics, a biotechnology company, has secured an oversubscribed $5 million seed round.
Kano Therapeutics, a biotechnology company pioneering single-stranded DNA (ssDNA) as a safe, efficient and flexible biomolecule for gene insertions, announced it has secured an oversubscribed $5 million seed round. The Engine Ventures and VSquared Ventures co-led the round, with Taihill Venture and Metaplanet also participating.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
